1. At a Glance
From zero to niche hero—Shilpa Medicare has built an oncology-focused API and formulations empire with global credentials. But while its pipes are full of regulatory approvals, its P&L still looks like it needs a dose of adrenaline. Welcome to the pharma stock that’s high on USFDA but low on ROE.
2. Introduction with Hook
Imagine you’re the world’s top student—certified by USFDA, EMA, TGA, Cofepris, PMDA, and your local society uncle. But every exam, you still score 40 out of 100.
That’s Shilpa Medicare for you:
- Approvals? Plenty.
- Global clients? Yep.
- PAT Margin? 6%.
- ROE? 4.3%.
And despite all this, the stock is up 45% in a year. Either the market knows something, or it just got too high on its own formulations.
3. Business Model (WTF Do They Even Do?)
Shilpa makes niche Active Pharmaceutical Ingredients (APIs) and formulations, mainly in oncology.
Segments:
- APIs & Intermediates: 30+ oncology APIs supplied globally
- Formulations: 16 injectable forms, 19 oral dosage forms, including cutting-edge delivery formats like oral disintegrating films
- CRAMS: Contract research and manufacturing services
- Biologics & Biosimilars: Through its subsidiaries (Shilpa Biologics, Biocare)
- Power Play: Vertically integrated manufacturing setup with 19 blocks—segregated for oncology and non-oncology
And yes, they’re one of the few Indian firms making recombinant human
